Related references
Note: Only part of the references are listed.Cardiometabolic Outcomes in Children and Adolescents Following Discontinuation of Long-Term Risperidone Treatment
Chadi A. Calarge et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2014)
Quetiapine Treatment in Youth Is Associated With Decreased Insulin Secretion
Ying Fai Ngai et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2014)
Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach
Benno G. Schimmelmann et al.
CURRENT OPINION IN PSYCHIATRY (2013)
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Stefan Leucht et al.
LANCET (2013)
Pharmacoepidemiology of Antipsychotic Use in Youth with ADHD: Trends and Clinical Implications
Michael L. Birnbaum et al.
CURRENT PSYCHIATRY REPORTS (2013)
Antipsychotics and the Risk of Type 2 Diabetes Mellitus in Children and Youth
William V. Bobo et al.
JAMA PSYCHIATRY (2013)
National Trends in the Office-Based Treatment of Children, Adolescents, and Adults With Antipsychotics
Mark Olfson et al.
ARCHIVES OF GENERAL PSYCHIATRY (2012)
Metabolic Screening in Children Receiving Antipsychotic Drug Treatment
Elaine H. Morrato et al.
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE (2012)
Waist Circumference Is a Sensitive Screening Tool for Assessment of Metabolic Syndrome Risk in Children Treated With Second-Generation Antipsychotics
Constadina Panagiotopoulos et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2012)
Comparison of Long-Term (At Least 24 Weeks) Weight Gain and Metabolic Changes Between Adolescents and Adults Treated with Olanzapine
Ludmila A. Kryzhanovskaya et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2012)
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
Marc De Hert et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials
Jacqueline Caemmerer et al.
SCHIZOPHRENIA RESEARCH (2012)
Systematic Review of Early Cardiometabolic Outcomes of the First Treated Episode of Psychosis
Debra L. Foley et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
Metabolic and Neurological Complications of Second-Generation Antipsychotic Use in Children A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Tamara Pringsheim et al.
DRUG SAFETY (2011)
Obesity and coronary risk in patients treated with second-generation antipsychotics
Christoph U. Correll et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2011)
Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons
David Fraguas et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2011)
Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies
Alessandro Zuddas et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2011)
Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice
M. De Hert et al.
EUROPEAN PSYCHIATRY (2011)
No Unexpected Adverse Events and Biochemical Side Effects of Olanzapine as Adjunct Treatment in Adolescent Girls with Eating Disorders
Ingemar Swenne et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2011)
Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents
Lawrence Maayan et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2011)
Safety and Tolerability of Antipsychotic Treatment in Young Patients With Schizophrenia
Christoph U. Correll
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Safety and Tolerability of Aripiprazole for Irritability in Pediatric Patients With Autistic Disorder: A 52-Week, Open-Label, Multicenter Study
Ronald N. Marcus et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Developments in Pediatric Psychopharmacology: Focus on Stimulants, Antidepressants, and Antipsychotics
Christoph U. Correll et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Adolescent BMI Trajectory and Risk of Diabetes versus Coronary Disease
Amir Tirosh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Antipsychotic Medication Use Among Children and Risk of Diabetes Mellitus
Susan E. Andrade et al.
PEDIATRICS (2011)
Increasing off-label use of antipsychotic medications in the United States, 1995-2008
G. C. Alexander et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Antipsychotic drugs and obesity
Christoph U. Correll et al.
TRENDS IN MOLECULAR MEDICINE (2011)
Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials
Christoph U. Correll et al.
BIPOLAR DISORDERS (2010)
Treatment with antipsychotics and the risk of diabetes in clinical practice
Lars Vedel Kessing et al.
BRITISH JOURNAL OF PSYCHIATRY (2010)
Management of antipsychotic-related weight gain
Lawrence Maayan et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2010)
Age-Dependent Metabolic Effects of Second-Generation Antipsychotics in Second-Generation Antipsychotic-Naive French Canadian Patients
Genevieve Roy et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2010)
Adverse Events Associated With Psychotropic Treatment in African American Children and Adolescents
Jeanette M. Jerrell
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION (2010)
Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naive Schizophrenia Patients
Jimmi Nielsen et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
Christine Rummel-Kluge et al.
SCHIZOPHRENIA RESEARCH (2010)
A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia
Stefan Leucht et al.
AMERICAN JOURNAL OF PSYCHIATRY (2009)
Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study
Magali Haas et al.
BIPOLAR DISORDERS (2009)
Increased Prevalence of Obesity and Glucose Intolerance in Youth Treated With Second-Generation Antipsychotic Medications
Constadina Panagiotopoulos et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2009)
Broadened Use Of Atypical Antipsychotics: Safety, Effectiveness, And Policy Challenges
Stephen Crystal et al.
HEALTH AFFAIRS (2009)
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
Christoph U. Correll et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
A Naturalistic Study of Predictors and Risks of Atypical Antipsychotic Use in an Attention-Deficit/Hyperactivity Disorder Clinic
Margaret Weiss et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2009)
Acute Treatment of Pediatric Bipolar I Disorder, Manic or Mixed Episode, With Aripiprazole: A Randomized, Double-Blind, Placebo-Controlled Study
Robert L. Findling et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study
Marianne Ulcickas Yood et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizoaffective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study
Linmarie Sikich et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
A Multiple-Center, Randomized, Double-Blind, Placebo-Controlled Study of Oral Aripiprazole for Treatment of Adolescents With Schizophrenia
Robert L. Findling et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Antipsychotics and diabetes: An age-related association
Ariel Hammerman et al.
ANNALS OF PHARMACOTHERAPY (2008)
Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents
Roger S. McIntyre et al.
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE (2008)
First- V. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis
M. Smith et al.
BRITISH JOURNAL OF PSYCHIATRY (2008)
Tolerability of Oral Ziprasidone in Children and Adolescents with Bipolar Mania, Schizophrenia, or Schizoaffective Disorder
Melissa P. DelBello et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2008)
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics
David Fraguas et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes
Christoph U. Correll
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY (2008)
Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia
Sanjiv Kumra et al.
SCHIZOPHRENIA BULLETIN (2008)
Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: Implications for medication studies
Peter S. Jensen et al.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY (2007)
Safety and usage of atypical antipsychotic medicines in children - A nationwide prospective cohort study
Mira Harrison-Woolrych et al.
DRUG SAFETY (2007)
Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in Veterans Health Administration patients with schizophrenia
Bruce L. Lambert et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2006)
National trends in the outpatient treatment of children and adolescents with antipsychotic drugs
Mark Olfson et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Trends in prescribing of antipsychotic medications for US children
WO Cooper et al.
AMBULATORY PEDIATRICS (2006)
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies
CU Correll et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
Weight gain and new onset diabetes associated with olanzapine and risperidone
WR Farwell et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2004)
A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial
L Sikich et al.
NEUROPSYCHOPHARMACOLOGY (2004)
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: Findings from a large health plan database
FD Gianfrancesco et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
Risk factors for diabetes mellitus by age and sex: results of the National Population Health Survey
BCK Choi et al.
DIABETOLOGIA (2001)
Share Paper
